PEP-1324: Glycemic Response Testing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Janice Campbell
- Email: JCampbell@gilabs.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5C 2N8
- Recruiting
- GI Labs
-
Contact:
- Janice Campbell
- Email: JCampbell@gilabs.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is 18-75 years of age
- Subject is male or non-pregnant females, 18-75 years of age, inclusive
- Subject has a body mass index (BMI) ≥ 20.0 and < 35 kg/m² at screening (visit 1).
- Subject has to be non-smoker.
- Subject is willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial.
- Subject is willing to maintain current dietary supplement use throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit.
- Subject has normal fasting serum glucose (<7.0mmol/L capillary corresponding to whole blood glucose <6.3mmol/L).
- Subject is willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to all test visits.
- Subject has no health conditions that would prevent him from fulfilling the study requirements as judged by the Investigator on the basis of medical history.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
A nutrient formulation without the active ingredient
|
|
|
Experimental: Nutrient formulation
Nutrient formulations with variable amounts of active ingredients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incremental area under the blood glucose response cruve
Time Frame: 0-2 hours
|
0-2 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
peak blood glucose
Time Frame: 0-2 hours
|
0-2 hours
|
|
peak insulin
Time Frame: 0-2 hours
|
0-2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PEP-1324 (PepsiCo)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.